Forecasting the Future of Multiple Myeloma
Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.
Transcript:
I think it’s cool that there are other therapies that are hopefully going to be approved in the near future that are more—not to say traditional, but they’ll [provide] more options for our patients who are ineligible for CAR T or bispecific antibody therapy.
Secondly, most of the approved agents, from a cellular immunotherapy perspective, are based on harnessing the power of T cells, but there are other agents on their heels trying to harness the anti-tumor effects of other immune populations, like macrophages or natural killer cells. That's going to be a cool next step. [It’s going to be interesting to see] how we can use other arms of a patient’s immune system to affect the anti-myeloma activity of therapy.
Transcript edited for clarity.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
